SynAct Pharma
13.94 SEK
-7.31 %
Less than 1K followers
SYNACT
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
-7.31 %
-22.12 %
-35.76 %
-38.32 %
-36.35 %
-29.24 %
-81.59 %
-84.64 %
+202.41 %
SynAct Pharma operates in the pharmaceutical industry and focuses on the development of innovative treatments for inflammatory diseases. The company researches new therapies that can reduce inflammation and improve patient outcomes. The business is global with a primary presence in Europe and North America. SynAct Pharma was founded in 2012 and is headquartered in Lund, Sweden.
Read moreMarket cap
783.62M SEK
Turnover
5.78M SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
Revenue
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
27.5
2026
Interim report Q1'26
11.6
2026
General meeting '26
20.8
2026
Interim report Q2'26
All
Webcasts
Press releases
3rd party
ShowingAll content types
BioStock: SynAct Pharma completes dosing in phase IIb ADVANCE study ahead of June readout
SynAct Pharma completes dosing for last patient in Phase 2b ADVANCE study
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools